Min­er­va's shares sink on re­jec­tion of schiz­o­phre­nia drug

The FDA has once again turned away Min­er­va’s schiz­o­phre­nia drug rolu­peri­done, re­quest­ing “at least one” ad­di­tion­al well-con­trolled study.

While rolu­peri­done met the pri­ma­ry end­point in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER